Tamsulosin Hydrochloride Capsule
Product Images NDC 68071-5118

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68071-5118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5118 1)

This appears to be a label or packaging information for Tamsulosin HCI 0.4mg capsules made by NuCare Pharmaceuticals. It includes important information about warnings, dosage, ingredients, lot numbers, and an expiration date. The label advises users to consult their doctor about side effects and to keep the medication out of reach of children. The capsules should be stored in a controlled temperature environment.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

The text is a figure caption showing the plasma concentration of Tamsulosin Hydrochloride Capsules 0.4 mg following single-dose administration under fasted and fed conditions. Not available to provide a useful description.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

The description is: "A figure titled 'Figure 3A Mean Increase in Peak Urine Flow Rate' shows the mean change in peak urine flow rate in mL/sec after treatment with 0.08mg, 0.4mg, and placebo over a period of 7 to 13 weeks as part of Study 1. The number of participants in each group is indicated."*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

The graph in Figure 3B shows the mean increase in peak urine flow rate (measured in mL/sec) during Study 2. The graph displays the effect of a 20-week treatment on the flow rate. The x-axis represents the duration of treatment in weeks, and the y-axis represents the increase in peak urine flow rate. The treatment appears to result in a gradual and continuous increase in the flow rate. The labels and markings on the graph are not entirely clear, and some characters are not readable.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.